SEC Form 4 · accession 0000899243-18-004949
Wave Life Sciences, Inc. · WVE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Keith Regnante
Officer — Chief Financial Officer
Period of report
Feb 16, 2018
Accepted (ET)
Feb 21, 2018 · 7:16 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631574
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF2 | Feb 16, 2018 | S | 316 | $51.85 | D | 16,984 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On February 16, 2018, the reporting person sold 316 ordinary shares solely to cover taxes associated with the vesting of restricted share units on February 15, 2018. These sales were made pursuant to a 10b5-1 Trading Plan.
- F2The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $51.65 to $51.85 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.